Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients.
OBJECTIVE
To study effects of vasopressin on hemodynamic, clinical, and laboratory variables in children with advanced vasodilatory shock.


METHODS
Retrospective study in a multidisciplinary tertiary pediatric critical care unit.


METHODS
Patients (n = 117; 32 noncardiac, 85 postcardiac surgery) requiring intravenous vasopressin infusion longer than 60 min for advanced shock (January 2004 to December 2005).


METHODS
Vasopressin infusion (n =157).


RESULTS
Both cardiac and noncardiac patients showed a significant decrease in inotrope requirement without change in central venous saturation or lactate during infusion. Both groups had increased urea and creatinine and decreased urine output with longer duration/higher cumulative dose of vasopressin. There was a significant increase in conjugated bilirubin level in the noncardiac group during vasopressin infusion; noncardiac patients showed higher AST levels with higher cumulative dose or longer duration of infusion. Postcardiac surgical patients showed a trend towards normal INR values which persisted after vasopressin infusion. Platelet counts were significantly lower during infusion in both groups.


CONCLUSIONS
Vasopressin infusion improved the hemodynamic state in advanced shock without compromising cardiac function. Urine output and creatinine levels were adversely affected but were reversible. This effect was more pronounced with higher dose or duration of infusion. There was no major effect on liver function but a significant reduction in platelet counts. These data suggest that vasopressin is useful in states of vasodilatory shock with limitations regarding to its adverse renal effects and on platelet counts.
Jerath
Nameet
N
Department of Critical Care Medicine, University of Toronto, M5G1X8, Toronto ON, Canada.
Frndova
Helena
H
McCrindle
Brian W
BW
Gurofsky
Rebecca
R
Humpl
Tilman
T
D002648:Child; D002675:Child, Preschool; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D015278:Intensive Care Units, Pediatric; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007677:Kidney Function Tests; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008111:Liver Function Tests; D008297:Male; D016347:Medical Records Systems, Computerized; D012189:Retrospective Studies; D012769:Shock / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014667:Vasopressins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D014667:Vasopressins